Inve India ▾
RURUBICON

Rubicon Research Q3 FY26 results (Oct–Dec 2025) and concall

Healthcare · Concall AI · Call held 3 Feb 2026

Rubicon Research Limited reported a robust Q3 FY26, driven by strong revenue growth across both new launches and existing products. The company saw significant improvements in profitability metrics, with PAT growing 91% year-on-year. Management highlighted the increasing productivity of R&D investments and provided updates on the Pithampur facility, which is expected to be operational by mid-2026. Despite increased outsourcing impacting gross margins, the operating EBITDA margin is projected to remain stable within the 22-23% range, reflecting confidence in the business trajectory.

You’re reading a preview. Opening the full call uses 1 concall credit.

Sign in to use your monthly call allowance.

What they filed

Q3 FY26: revenue up 52.1%, net profit up 92.1% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Revenue296 313 358 352 412 +39%476 +52%
EBITDA62 70 72 79 94 +52%108 +54%
Net profit34 38 36 43 54 +59%73 +92%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.